An analysis of 20 clinical cases of refractory mycoplasma pneumonia in children.

BACKGROUND Refractory mycoplasma pneumonia (RMPP) is one of the important pathogens of community-acquired pneumonia (CAP) in children. Its treatment is difficult. The aims of this study were to analyze the clinical manifestations, diagnosis, and treatment of 20 cases of RMPP in children in order to provide a reference for the diagnosis and treatment of RMPP. METHODS The clinical data of 20 patients with RMPP admitted to the Pediatrics Department of the First Affiliated Hospital of Guangzhou Medical University in the recent three years were retrospectively analyzed. The clinical data of 36 patients with common mycoplasma pneumonia in the same period were compared. The clinical manifestations, laboratory examinations, and imaging characteristics of RMPP were discussed. Intrapulmonary and extrapulmonary complications and treatment were also analyzed in order to provide assistance in the diagnosis and treatment of RMPP. RESULTS There were significant differences between the refractory group and the general group in terms of heat duration, hospitalization time, hypoxemia, lung rales, CRP, ESR, PCT, LDH, ALT, PLT, WBC, D dimer and other laboratory examinations, intrapulmonary and extrapulmonary complications, and treatment (all P<0.05). There was no significant difference in the age, sex, and wheezing between the two groups (P>0.05). CONCLUSIONS Long duration of fever, tachycardia, and lung rale protrusion may be the clinical characteristics of RMPP. Unilateral pulmonary shadow and atelectasis should be paid more attention, which may be a high-risk factor for the development of RMPP. The inflammation index of RMPP cases increased and there were many complications inside and outside the patients' lungs. It was necessary to give enough macrolides to fight the infection by using Glucocorticoid and Intravenous immunoglobulin reasonably while liver, heart, and fiberoptic bronchoscopy was completed to improve the effectiveness of the diagnosis and treatment.

[1]  W. Guo,et al.  Clinical characteristics of refractory mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy , 2020, BMC Infectious Diseases.

[2]  Y. Li,et al.  Epidemiology and clinical characteristics of pathogens positive in hospitalized children with segmental/lobar pattern pneumonia , 2020, BMC Infectious Diseases.

[3]  J. Dai,et al.  Development and validation of a simple‐to‐use nomogram for predicting refractory Mycoplasma pneumoniae pneumonia in children , 2020, Pediatric pulmonology.

[4]  M. Ospina,et al.  Health gradients in emergency visits and hospitalisations for paediatric respiratory diseases: A population-based retrospective cohort study. , 2020, Paediatric and perinatal epidemiology.

[5]  Rui Han,et al.  Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children , 2019, Pakistan journal of medical sciences.

[6]  R. Ranjbar,et al.  Epidemiology of Mycoplasma pneumoniae prevalence in Iranian patients: a systematic review and meta-analysis. , 2019, Journal of medical microbiology.

[7]  Shuaicheng Li,et al.  An integrated respiratory microbial gene catalogue to better understand the microbial aetiology of Mycoplasma pneumoniae pneumonia , 2019, GigaScience.

[8]  L. Mannonen,et al.  Mycoplasma pneumoniae outbreak, Southeastern Finland, 2017–2018: molecular epidemiology and laboratory diagnostic lessons , 2019, European Journal of Clinical Microbiology & Infectious Diseases.

[9]  Jinrong Liu,et al.  High Mycoplasma pneumoniae loads and persistent long-term Mycoplasma pneumoniae DNA in lower airway associated with severity of pediatric Mycoplasma pneumoniae pneumonia , 2019, BMC Infectious Diseases.

[10]  K. Shen,et al.  The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to 2016 , 2019, Epidemiology and Infection.

[11]  S. Cha,et al.  A case of pseudomembranous tracheitis caused by Mycoplasma pneumoniae in an immunocompetent patient. , 2019, Annals of translational medicine.

[12]  Ying Wang,et al.  Serum Tumor Necrosis Factor-α and Interferon-γ Levels in Pediatric Mycoplasma pneumoniae Pneumonia: A Systematic Review and Meta-Analysis , 2018, Canadian respiratory journal.

[13]  M. B. Friis,et al.  Clinical manifestations in infants and children with Mycoplasma pneumoniae infection , 2018, PloS one.

[14]  Y. Zou,et al.  Refractory Mycoplasma pneumoniae pneumonia with concomitant acute cerebral infarction in a child , 2018, Medicine.

[15]  Lilin Huang,et al.  Spontaneous pneumomediastinum, emphysema, and pulmonary bullae associated with refractory Mycoplasma pneumoniae pneumonia in a child , 2017, Pediatric pulmonology.

[16]  H. Yang,et al.  Mechanism of resistance acquisition and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children , 2017, Korean journal of pediatrics.

[17]  Lindsay E Rogozinski,et al.  Diagnosis and treatment of Mycoplasma pneumoniae in children. , 2017, Minerva pediatrica.

[18]  J. Gilsdorf,et al.  Community-acquired pneumonia in children. , 1987, Seminars in respiratory infections.